$PFE News

Pfizer: Still Cheap Valuation Meets A Looming Patent Cliff

Recent Filing Shows That Rep. Carol Miller Sold Over $60K Worth of Pfizer Stock

Pfizer and Valneva’s Lyme Disease Vaccine Candidate Marketing Authorization Application Validated by European Medicines Agency

Pfizer and Valneva’s Lyme Disease Vaccine Candidate Marketing Authorization Application Validated by European Medicines Agency

Gene Therapy Remains Top-of-Mind in Hemophilia Despite Recent Market Contraction, as Physicians and Patients Raise the Bar for Success

How Pfizer’s Higher 2026 Guidance And LITFULO Trial Results At Pfizer (PFE) Have Changed Its Investment Story

Pfizer CEO Buys $1 Million of Stock

5 Insightful Analyst Questions From Pfizer’s Q2 Earnings Call

Pfizer (PFE) Agreed To A $44 Million Chantix Settlement

$49 Billion In Payouts, A Lagging Stock: The PFE Trade-Off

Pfizer Just Raised Its 2026 Guidance -- but the Boost Leans Heavily on a Drug Running Out the Patent Clock

Pfizer agrees to $44M Chantix settlement. See if you qualify

Pfizer vs AbbVie: What's the Better Dividend Stock for Investors in 2026?

Pfizer's Pipeline Could Change Everything

Pfizer (PFE) Q2 2026 Earnings Call Transcript

Pfizer Inc. (PFE) vs. BioNTech SE (BNTX): Which Pharma Giant Is Better Positioned for the Post-COVID Era?

Pfizer's Earnings Have Declined 58% This Year. Is a Dividend Cut Around the Corner?

Guggenheim Maintains Buy on Pfizer, Lowers Price Target to $31

Pfizer (PFE) Could Be 12% Undervalued Following Raised 2026 Revenue Guidance

Pfizer Stock Slips Despite Earnings Beat and $2.5 Billion Cuts